Joseph C. Sardano, CHIEF EXECUTIVE OFFICER at Sensus Healthcare, Inc. (SRTS), bought 20,000 shares at $3.02 ($60K) on 2026-08-20, disclosed to the SEC on 2026-08-24.
CEO Joseph C. Sardano purchased 20,000 shares at $3.02, signaling confidence in the company's turnaround following recent revenue declines. This move comes as the stock has rallied 15.88% over the past five days, suggesting the market is pricing in a recovery.
SRTS has surged 15.88% over the last five days and is currently trading 24.58% above its 52-week low of $2.665, though it remains down 39.53% from its 52-week high of $5.49.
Management expects a recovery in Q3 revenue following financing delays that crushed Q2 results; the company is also positioning for a stronger second half by securing delayed orders and seeing growing international demand.
Revenue declined significantly in Q2 due to delayed third-party financing, and analyst fair value estimates have been trimmed from $6.88 to $5.75, highlighting execution and timing risks.
Nothing distinguishes this filing.
| Filing → |
| SRTS | BUY | 2023-08-08 | $39K | — | Filing → |
| SRTS | BUY | 2023-05-11 | $126K | — | Filing → |
| SRTS | SELL | 2022-09-07 | $918K | — | Filing → |